Navigation Links
Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
Date:3/30/2009

WALTHAM, Mass., March 30 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc. (NYSE: IMA), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, has declared a dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock (NYSE: IMA-PB). The dividend will be paid in shares of Series B stock in an amount per share equal to the quotient of (a) $3.00 divided by (b) 97% of the average of the volume-weighted average price per share of the Series B stock on the New York Stock Exchange for each of the five consecutive trading days ending on the second trading day immediately prior to the record date of the dividend. Inverness will pay cash in lieu of any fractional shares resulting from the dividend. The dividend is payable on April 15, 2009 to holders of record of Series B stock at the close of business on April 1, 2009.

Such payment will cover the amount of all dividends accrued from January 1, 2009 through March 31, 2009.

For more information about Inverness Medical Innovations, please visit our website at http://www.invernessmedical.com.

By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life. Inverness' global leading products and services, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Inverness is headquartered in Waltham, Massachusetts.


'/>"/>
SOURCE Inverness Medical Innovations
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
2. Inverness - Chemogen Establish Exclusive License for TB Antibodies
3. Inverness Medical Innovations Announces Proposed Public Offering of Common Stock
4. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
5. Inverness Medical Innovations Acquires ParadigmHealth
6. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 8, 2008
7. Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
8. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
9. Inverness Medical Innovations Completes Acquisition of BBI Holdings Plc
10. Inverness Medical Innovations Announces Fourth Quarter 2007 Results
11. Inverness Medical Innovations to Participate at Bank of America 2008 Smid Cap Conference on March 26, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Selexis SA, a serial innovation company with proven ... for drug discovery to commercial manufacturing, announced today all ... Sequencing (NGS) data packages. The NGS analysis of ... the integrity of the gene, validation of the left ...
(Date:1/22/2015)... , Jan. 22, 2015   GenoSpace , a precision medicine ... to enable the broad use of genomic, imaging and other ... appointment of Michelle Munson , CEO of Aspera, an ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 "We ...
(Date:12/24/2014)... Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), ... announced today that the Company closed its previously ... Management, Jack W. Schuler , Birchview Fund ... $10.5 million, before offering expenses.  The proceeds will ...
(Date:12/24/2014)... MA (PRWEB) December 23, 2014 ... is designed to introduce cutting edge communication technology, ... of platform upgrades. This webinar series demonstrates online ... quest to leverage web conferencing’s most innovative and ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2GenoSpace Expands Board with Appointment of Michelle Munson 2Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3
... is about to emerge in the world of pesticides and ... to understand the implications for public health, ensure that this ... risks, researchers say in a new report. In a ... and Environmental Health , scientists from Oregon State University and ...
... Oct. 4 Amgen (Nasdaq: AMGN ) ... ,181, pivotal Phase 3 trials evaluating Vectibix® (panitumumab) in ... and second-line treatment for metastatic colorectal cancer (mCRC), respectively, ... Oncology . "Both studies demonstrated that ...
... NEW YORK, Oct. 4 Reportlinker.com announces that ... its catalogue: Global Soft Tissue ... This report analyzes the worldwide markets ... the following segments: Cartilage Allografts, Meniscus Allografts, and ...
Cached Biology Technology:New approaches needed to gauge safety of nanotech-based pesticides 2New approaches needed to gauge safety of nanotech-based pesticides 3Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 2Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 3Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 4Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 5Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 6Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 7Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 8Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 9Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 10Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 11Reportlinker Adds Global Soft Tissue Allografts Industry 2Reportlinker Adds Global Soft Tissue Allografts Industry 3Reportlinker Adds Global Soft Tissue Allografts Industry 4Reportlinker Adds Global Soft Tissue Allografts Industry 5Reportlinker Adds Global Soft Tissue Allografts Industry 6Reportlinker Adds Global Soft Tissue Allografts Industry 7Reportlinker Adds Global Soft Tissue Allografts Industry 8Reportlinker Adds Global Soft Tissue Allografts Industry 9Reportlinker Adds Global Soft Tissue Allografts Industry 10Reportlinker Adds Global Soft Tissue Allografts Industry 11
(Date:1/22/2015)... Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication company ... of the Wocket™ smart wallet at CES 2015 in Las ... one of the "11 Hot Products at CES" in a review published ... Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" by ...
(Date:1/22/2015)... , January 22, 2015 , ... tenth year  The European Patent Office to present a ... Two British nominations to be featured: Christofer Toumazou and ... featuring former finalists and winners of the Award   ...
(Date:1/22/2015)... , Jan. 22, 2015 Infinisource has launched its ... the G2 model. The G2 sets a higher standard for ... human capital management solution. With plug-and-play installation, touch screen interface ... clock provides a robust time collection solution for the small ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3Infinisource's NXG series sets new time clock standard 2
... called ribonucleotides become embedded in genomic DNA, which contains ... cause problems for cells. It is known that ribonucleotides ... resulting in genomic instability and altered DNA metabolism, but ... ribonucleotides. A new study provides a mechanistic explanation ...
... and colleagues have produced the most comprehensive mathematical model ... to environmental change. The research, federally ... 2 in the journal Science . ... unites various sub-disciplines of population biology, including population ecology, ...
... Los Angeles, CA (December 2nd, 2011) Most of ... new results out in the journal Clinical Rehabilitation , ... to reduce early retirement on health grounds in Finland had ... evaluative study of vocational rehabilitation, which followed 872 participants and ...
Cached Biology News:Study identifies mechanisms cells use to remove bits of RNA from DNA strands 2Powerful mathematical model greatly improves predictions for species facing climate change 2Powerful mathematical model greatly improves predictions for species facing climate change 3Costly intervention program has no measurable effect on early retirement 2Costly intervention program has no measurable effect on early retirement 3
This issue concentrated on the purification of proteins for specific purposes (i.e. large-scale purification, purification for therapeutic use, etc.)...
... Dunbar (1994) • This book describes ... methods for preparing samples for protein ... radiometric and bioluminescence-enhanced detection systems are ... the detection and characterization of glycoprotein ...
All serum is collected from U.S.D.A. fryers and broilers. Pricing: $15/unit for 1 - 10 units; $12/unit for 11 - 50 units...
Human HAPLN1 MAb (Clone 316119) Protein Family: Hyaluronan (HA) & HA Binding Proteins, Proteoglycan Regulators...
Biology Products: